Mirati Therapeutics Announces IND Submission of MRTX849 to Treat NSCLC & CRC

Shots:

• The IND submission under FDA is in response to onset P-I/II clinical trial for MRTX849, to evaluate its safety, PK & tolerability
• With the IND acceptance, the trial will use an accelerated titration design with single patient cohorts and intra-patient dose for MRTX849 & P-II expansion cohorts will enroll patients with +ve KRAS G12C mutations
• MRTX849 PO is a KRASi and further stops G12C mutation. The P-II study portion in NSCLC & CRC patients will provide proof-of-concept (expected in 2019) and support for its accelerated approval

Click here to read full press release/ article | Ref: Mirati Therapeutics| Image: PR Newswire